Primarily, paracrine TGF-β attenuates the cytotoxicity and the tumor-killing ability of CD8+ T cells through its action on αβ T cells, thereby reducing the percentage of GzmB+ CD8+ TILs. The gene discussed is CD8A; the disease is neoplasm.